Role of inflammatory cytokines in the effect of estradiol on atheroma

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 4, 2008, Pages 396-401

  Gourdy, P ^a   Calippe, B ^a   Laurell, H ^a   Tremollieres F ^a   Douin Echinard, V ^a   Lenfant, F ^a   Bayard, F ^a   Guery, J C ^b   Arnal, J F ^a  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

Author keywords

Atheroma; Atherosclerosis; Cardiovascular risk; Oestrogens; Thrombosis

Indexed keywords

CYTOKINE; ESTRADIOL; ESTROGEN DERIVATIVE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; NEUTRALIZING ANTIBODY; NITRIC OXIDE; PROSTACYCLIN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CELL POPULATION; CONFERENCE PAPER; DRUG EFFECT; ENDOTHELIUM; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; ISCHEMIC HEART DISEASE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; POSTMENOPAUSE; PREMENOPAUSE; PROSTAGLANDIN SYNTHESIS; RISK ASSESSMENT; STROKE; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; CYTOKINES; ENDOTHELIUM; ESTRADIOL; FEMALE; GENE DELETION; HUMANS; HYPERCHOLESTEROLEMIA; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; MICE; TRANSFORMING GROWTH FACTOR BETA;

EID: 40149085426     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04885.x     Document Type: Conference Paper

References (52)

1. Grodstein F, Stampfer MJ, Manson JE et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 1996 335 : 453 61.
2. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998 280 : 605 13.
3. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 288 : 321 33.
4. Hodgin J, Maeda N. Estrogen and mouse models of atherosclerosis. Endocrinology 2002 143 : 4495 501.
5. Clarkson TB, Appt SE. Controversies about HRT - Lessons from monkey models. Maturitas 2005 51 : 64 74.
6. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science 2005 308 : 1583 7.
7. Arnal JF, Douin-Echinard V, Brouchet L et al. Understanding the oestrogen action in experimental and clinical atherosclerosis. Fundam Clin. Pharmacol. 2006 20 : 539 48.
8. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc. Natl Acad. Sci. USA 1996 93 : 10 022 7.
9. Elhage R, Arnal JF, Pierragi M-T et al. Estradiol-17β prevents fatty streak formation in apolipoprotein E-deficient mice. Arterioscl. Thromb. Vasc. Biol. 1997 17 : 2679 84.
10. Haarbo J, Leth-Espensen P, Stender S, Christiansen C. Estrogen monotherapy and combined estrogen-progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. J. Clin. Invest. 1991 87 : 1274 9.
11. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. Circulation 1999 100 : 1727 33.
12. Couse JF, Korach KS. Estrogen receptor null mice: What have we learned and where will they lead us? Endocr. Rev. 1999 20 : 358 417.
13. Tora L, White J, Brou C et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 1989 59 : 477 87.
14. Reid G, Denger S, Kos M, Gannon F. Human estrogen receptor-alpha: Regulation by synthesis, modification and degradation. Cell Mol. Life Sci. 2002 59 : 821 31.
15. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc. Natl Acad. Sci. USA 1993 90 : 11 162 6.
16. Couse JF, Curtis SW, Washburn TF et al. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol. Endocrinol. 1995 9 : 1441 54.
17. Pendaries C, Darblade B, Rochaix P et al. The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. Proc. Natl Acad. Sci. USA 2002 99 : 2205 10.
18. Kos M, Denger S, Reid G, Korach KS, Gannon F. Down but not out? A novel protein isoform of the estrogen receptor alpha is expressed in the estrogen receptor alpha knockout mouse. J. Mol. Endocrinol. 2002 29 : 281 6.
19. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 2000 127 : 4277 91.
20. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J. Clin. Invest 2001 107 : 333 40.
21. Tedgui A, Mallat Z. Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol. Rev. 2006 86 : 515 81.
22. Hansson GK, Libby P. The immune response in atherosclerosis: A double-edged sword. Nat. Rev. Immunol. 2006 6 : 508 19.
23. Elhage R, Clamens S, Reardon-Alulis C et al. Loss of atheroprotective effect of estradiol in immunodeficient mice. Endocrinology 2000 141 : 462 5.
24. Elhage R, Gourdy P, Huc X et al. The atheroprotective effect of 17-estradiol depends on complex interactions in adaptive immunity. Am. J. Pathol. 2005 167 : 267 74.
25. Ghisletti S, Meda C, Maggi A, Vegeto E. 17[beta]-estradiol inhibits inflammatory gene expression by controlling NF-[kappa]B intracellular localization. Mol. Cell. Biol. 2005 25 : 2957 68.
26. Deshpande R, Khalili H, Pergolizzi RG, Michael SD, Chang MD. Estradiol down-regulates LPS-induced cytokine production and NFkB activation in murine macrophages. Am. J. Reprod. Immunol. 1997 38 : 46 54.
27. Vegeto E, Belcredito S, Etteri S et al. Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc. Natl Acad. Sci. USA 2003 100 : 9614 19.
28. Vegeto E, Bonincontro C, Pollio G et al. Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J. Neurosci. 2001 21 : 1809 18.
29. Soucy G, Boivin G, Labrie F, Rivest S. Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J. Immunol. 2005 174 : 6391 8.
30. Maret A, Coudert JD, Garidou L et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur. J. Immunol. 2003 33 : 512 21.
31. Gourdy P, Araujo LM, Zhu R et al. Relevance of sexual dimorphism to regulatory T cells: Estradiol promotes IFN-[gamma] production by invariant natural killer T cells. Blood 2005 105 : 2415 20.
32. Libby P. Inflammation in atherosclerosis. Nature 2002 420 : 868 74.
33. Gourdy P, Schambourg A, Filipe C et al. Transforming growth factor activity is a key determinant for the effect of estradiol on fatty streak deposit in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol. 2007 27 : 2214 21.
34. Elhage R, Clamens S, Besnard S et al. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 2001 156 : 315 20.
35. Mendelsohn ME. Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: How does it work? What does it mean? Circ. Res. 2000 87 : 956 60.
36. Arnal JF, Clamens S, Pechet C et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine aortic endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc. Natl Acad. Sci. USA 1996 93 : 4108 13.
37. Wagner AH, Schroeter MR, Hecker M. 17beta-estradiol inhibition of NADPH oxidase expression in human endothelial cells. Faseb J. 2001 15 : 2121 30.
38. Darblade B, Pendaries C, Krust A et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ. Res. 2002 90 : 413 19.
39. Elhage R, Bayard F, Richard V et al. Prevention of fatty streak formation of 17beta-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice. Circulation 1997 96 : 3048 52.
40. Egan KM, Lawson JA, Fries S et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004 306 : 1954 7.
41. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: Physiological complexity belies therapeutic simplicity. Science 2004 304 : 1269 73.
42. Rossouw JE, Prentice RL, Manson JE et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007 297 : 1465 77.
43. Koh KK, Sakuma I. Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials? Arterioscler. Thromb. Vasc. Biol. 2004 24 : 1171 9.
44. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004 291 : 1701 12.
45. Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women. Impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007 115 : 840 5.
46. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003 362 : 428 32.
47. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 1997 17 : 3071 8.
48. Oger E, Alhenc-Gelas M, Lacut K et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: A randomized trial. Arterioscler. Thromb. Vasc. Biol. 2003 23 : 1671 6.
49. Post MS, Christella M, Thomassen LG et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: A randomized, placebo-controlled study in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 2003 23 : 1116 21.
50. Lacut K, Oger E, Le Gal G et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb. Haemost. 2003 90 : 124 31.
51. Yilmazer M, Fenkci V, Fenkci S et al. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. Maturitas 2003 46 : 245 53.
52. Manson JE, Bassuk SS, Harman SM et al. Postmenopausal hormone therapy: New questions and the case for new clinical trials. Menopause 2006 13 : 139 47.